Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Important Safety Information | Patient Site
Prescribing Information
Wegovy® (semaglutide) injection 2.4 mg logo

In addition to diet and exercise, to reduce risk of MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CVD and either overweight or obesity, and for chronic weight management in patients with obesity ≥12 years and adults with overweight with at least one weight-related comorbidity. Click for Limitations of Use.

Prescribing Information
Important Safety Information | Patient Site

Resources

Frequently Asked Questions

Get the answers you need to help set patients up with a weight-management plan1,2

As you consider prescribing Wegovy® for your patients, you may have some questions. Below you will find answers that will help you treat effectively and communicate pertinent information to your patients and staff.

You can also call 1-833-493-4689 anytime with questions about Wegovy®.

ABOUT WEGOVY®

Wegovy® is the first and only once-weekly GLP-1 RA indicated in combination with a reduced-calorie diet and increased physical activity:

  • To reduce the risk of major adverse cardiovascular events (CV death, non-fatal MI, or non-fatal stroke) in adults with established CVD and either obesity
or overweight and
  • To reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged ≥12 years with obesity and adults with overweight with
at least one weight-related comorbidity

CV, cardiovascular; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; MI, myocardial infarction.

Wegovy® targets areas of the brain that regulate appetite and food intake. 94% similar to naturally occurring GLP-1, Wegovy® lowers your patients’ appetite to help them lose weight and keep it off.* GLP-1 is a native hormone that is released in response to food intake and acts as a physiological regulator of appetite.1 

The effect of Wegovy® was studied in animal models. The impact of Wegovy® in the brain is not fully understood.
GLP-1, glucagon-like peptide-1.
*At 2 years.2

In three randomized clinical trials to assess the safety and efficacy of Wegovy® for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, the following adverse reactions were reported in ≥2% of Wegovy®-treated patients and more frequently than with placebo1:

  • nausea
  • diarrhea
  • vomiting
  • constipation
  • abdominal pain†
  • headache
  • fatigue‡
  • dyspepsia
  • dizziness
  • abdominal distention
  • eructation
  • hypoglycemia in patients with type 2 diabetes mellitus§
  • flatulence
  • gastroenteritis
  • gastroesophageal reflux disease
  • gastritis‖
  • gastroenteritis viral
  • hair loss
  • dysesthesia

In STEP 1, nausea was the most common side effect seen in the trial and was generally mild or moderate and transient.3

†Includes abdominal pain, lower abdominal pain, upper abdominal pain, gastrointestinal pain, abdominal tenderness, abdominal discomfort, and epigastric discomfort.
‡Includes fatigue and asthenia.
§Defined as blood glucose <54 mg/dL with or without symptoms of hypoglycemia or severe hypoglycemia (requiring the assistance of another person) in patients with type 2 diabetes mellitus not on concomitant insulin (STEP 2, Wegovy® n=403, placebo n=402).
∥Includes chronic gastritis, gastritis, erosive gastritis, and reflux gastritis.
Includes paresthesia, hyperesthesia, burning sensation, allodynia, dysesthesia, skin burning sensation, pain of skin, and sensitive skin.

Once you’ve verified that your patient is covered and the prior authorization is approved, you can prescribe Wegovy® through your electronic heath record system.

When you prescribe, you can also provide your patient with a Wegovy® starter kit to help them get started right away.

Yes, Wegovy® has been studied in a head-to-head trial. The effects of weekly subcutaneous Wegovy® vs daily liraglutide 3 mg on body weight in adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) and at least one weight-related comorbidity (excluding diabetes) were studied in the STEP 8 clinical trial.4

BMI, body mass index.

Wegovy® is approved in combination with a reduced-calorie diet and increased physical activity to reduce the risk of MACE (defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.1

MACE, major adverse cardiovascular events.

TAKING WEGOVY®

  • The Wegovy® starting dose is 0.25 mg per week
  • Escalate the patient’s Wegovy® dose every 4 weeks
  • Please refer to the Prescribing Information for full dosing information
  • If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks
  • The maintenance dose of Wegovy® in adults is either 2.4 mg (recommended) or 1.7 mg once weekly. Consider treatment response and tolerability when selecting the maintenance dose
  • If adolescent patients are unable to tolerate the 2.4 mg once-weekly maintenance dose, the 1.7 mg dose may be used as a maintenance dose. Discontinue Wegovy® if the patient cannot tolerate the 1.7 mg dose

Every patient is different. Here are some general considerations for helping your patients manage nausea5,6

Bread and soup bowl icons

Eat bland, low-fat foods such as crackers, toast, and rice

Hot soup icon

Eat foods that contain water, such as soup and gelatin

Person with arrow icon

Don't lie down after you eat

Fork and knife place setting icon

Eat more slowly    

Wind icon

Go outside and get some fresh air

  • If adult patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks
  • If adolescent patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks. If patients do not tolerate the 2.4 mg once-weekly maintenance dose, the maintenance dose may be reduced to 1.7 mg once weekly. Discontinue Wegovy® if the patient cannot tolerate the 1.7 mg once-weekly dose
  • The 0.25 mg, 0.5 mg, and 1 mg once-weekly doses are initiation and escalation doses and are not approved as maintenance doses for chronic weight management

Instruct patients to store the Wegovy® pen in the refrigerator between 36 °F and 46 °F (2 °C and 8 °C). If needed, before removing the pen cap, Wegovy® can be stored between 46 °F and 86 °F (8 °C and 30 °C) in the original carton for up to 28 days. Do not freeze Wegovy®. Patients should keep Wegovy® in the original carton to protect it from light. Safely discard the Wegovy® pen after use.

Refer patients to the full Prescribing Information for more details regarding injection and pen storage.

Consider administering the first injection of Wegovy® in-office to reduce the risk of administration errors.

Patients will inject their dose of Wegovy® under the skin in the upper arms, stomach (keep 2 inches away from belly button), or upper legs (front of thighs). Indicate each of the 3 appropriate injection areas when prescribing Wegovy® and ensure patients understand that they should only inject subcutaneously.

Instruct patients who have problems injecting to change to a firmer injection site, such as upper leg or upper arm, or consider standing up while injecting into the stomach.

Refer patients to the full Prescribing Information for full usage instructions.

Wegovy® Pen Video
(1:47)

Our video will provide information about the Wegovy® injection technique.

Refer patients to the full Prescribing Information for more information regarding proper injection, storage, and handling techniques.

PATIENT SUPPORT & SAVINGS

Novo Nordisk has developed a 3-step process to help identify patients with Wegovy® coverage and help those without coverage gain access.

For every prescription, patients may pay as little as $0 per 28-day supply (1 box) of Wegovy®.#

#Subject to a maximum savings of $225 per 28-day supply (1 box) for up to 13 fills for commercially insured patients with Wegovy® coverage. Patients with commercial insurance who do not have coverage for Wegovy® through their plan or for those that are cash-paying, can expect to pay $650 per 28-day supply (1 box). Eligibility and other restrictions apply. Novo Nordisk reserves the right to modify or cancel the program at any time. See terms and conditions at  WegovyTerms.com.

WeGoTogether® is a program with behavior change resources designed to help your patients get started and stay on track with Wegovy®.

Your patients can get support with WeGoTogether®

Important Safety Information for Wegovy®

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
  • Wegovy® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy® and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy®

Indications and Usage

Wegovy® (semaglutide) injection 2.4 mg is indicated in combination with a reduced calorie diet and increased physical activity:

  • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight
  • to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity and adults with overweight in the presence of at least one weight-related comorbidity

Limitations of Use:

Wegovy® contains semaglutide. Coadministration with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended

 

Important Safety Information

Contraindications

  • Wegovy® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy®. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with Wegovy®

Warnings and Precautions

  • Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy® in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy® promptly, and if acute pancreatitis is confirmed, do not restart
  • Acute Gallbladder Disease: Treatment with Wegovy® is associated with an increased occurrence of cholelithiasis and cholecystitis. The incidence of cholelithiasis and cholecystitis was higher in Wegovy® pediatric patients aged 12 years and older than in Wegovy® adults. In clinical trials in adult patients, cholelithiasis was reported by 1.6% of Wegovy® patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy® patients and 0.2% of placebo patients. In a clinical trial in pediatric patients aged 12 years and older, cholelithiasis was reported by 3.8% of Wegovy® patients and 0% placebo patients. Cholecystitis was reported by 0.8% of Wegovy® pediatric patients and 0% placebo patients. Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in Wegovy® patients than in placebo patients, even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
  • Hypoglycemia: Wegovy® lowers blood glucose and can cause hypoglycemia. In a trial of adult patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy® patients versus 2.5% of placebo patients. Patients with diabetes taking Wegovy® with an insulin or insulin secretagogue (e.g. sulfonylurea) may have an increased risk of hypoglycemia, including severe hypoglycemia. The use of Wegovy® in patients with type 1 diabetes or in combination with insulin has not been evaluated. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with diabetes
  • Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy® in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion
  • Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with Wegovy®. If hypersensitivity reactions occur, discontinue use of Wegovy®, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist
  • Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: In a trial of adult patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy® patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
  • Heart Rate Increase: Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy® adult patients compared to placebo in clinical trials. More Wegovy® adult patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). In a clinical trial in pediatric patients aged 12 years and older with normal baseline heart rate, more patients treated with Wegovy® compared to placebo had maximum changes in heart rate of 20 bpm or more (54% versus 39%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy®
  • Suicidal Behavior and Ideation: Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy® in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Wegovy® delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Wegovy®

Adverse Reactions

  • Most common adverse reactions (incidence ≥5%) are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis

Drug Interactions

  • The addition of Wegovy® in patients treated with insulin has not been evaluated. When initiating Wegovy®, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
  • Wegovy® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy®

Use in Specific Populations

  • Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue Wegovy®. Discontinue Wegovy® in patients at least 2 months before a planned pregnancy
  • Pediatric: Adverse reactions with Wegovy® in pediatric patients aged 12 years and older were similar to those reported in adults. Pediatric patients ≥12 years of age treated with Wegovy® had greater incidences of cholelithiasis, cholecystitis, hypotension, rash, and urticaria compared to adults treated with Wegovy®. There are insufficient data in pediatric patients with type 2 diabetes treated with Wegovy® for obesity to determine if there is an increased risk of hypoglycemia with Wegovy® treatment similar to that reported in adults
  • Geriatric: In the cardiovascular outcomes trial, patients aged 75 years and older reported more hip and pelvis fractures on Wegovy® than placebo. Patients aged 75 years and older (Wegovy® and placebo) reported more serious adverse reactions overall compared to younger adult patients

Please click here for Wegovy® Prescribing Information, including Boxed Warning.

References

1. Wegovy® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.

2. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091.

3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.

4. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150.

5. Cleveland Clinic. Nausea and vomiting. Cleveland Clinic website. Accessed March 21, 2024. https://my.clevelandclinic.org/health/symptoms/8106-nausea--vomiting

6. MedlinePlus. When you have nausea and vomiting. MedlinePlus website. Accessed March 21, 2024. https://medlineplus.gov/ency/patientinstructions/000122.htm